HRP20131070T1 - Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima - Google Patents
Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima Download PDFInfo
- Publication number
- HRP20131070T1 HRP20131070T1 HRP20131070AT HRP20131070T HRP20131070T1 HR P20131070 T1 HRP20131070 T1 HR P20131070T1 HR P20131070A T HRP20131070A T HR P20131070AT HR P20131070 T HRP20131070 T HR P20131070T HR P20131070 T1 HRP20131070 T1 HR P20131070T1
- Authority
- HR
- Croatia
- Prior art keywords
- allopurinol
- medicine
- treatment
- use according
- hands
- Prior art date
Links
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 title claims 8
- 229960003459 allopurinol Drugs 0.000 title claims 8
- 206010040914 Skin reaction Diseases 0.000 title claims 7
- 230000035483 skin reaction Effects 0.000 title claims 7
- 231100000430 skin reaction Toxicity 0.000 title claims 7
- 239000003814 drug Substances 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 8
- 229940043363 multi-kinase inhibitor Drugs 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- 206010033553 Palmar-plantar erythrodysaesthesia syndrome Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000008309 hydrophilic cream Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (11)
1. Lijek koji sadrži Alopurinol ili njegovu farmaceutski prihvatljivu sol za uporabu u liječenju ili prevenciji Kožne reakcije na rukama i stopalima (Hand Foot Skin Reaction - HFSR) izazvane terapijom multiciljnih inhibitora kinaze (MKI).
2. Lijek za uporabu prema patentnom zahtjevu 1, naznačen time da je Kožna reakcija na rukama i stopalima izazvana sunitinibom.
3. Lijek za uporabu prema patentnom zahtjevu 1, naznačen time da je Kožna reakcija na rukama i stopalima izazvana sorafenibom.
4. Lijek za uporabu prema bilo kojem od patentnih zahtjeva 1-3, naznačen time da je lijek za mjestimičnu primjenu, preporučeno za mjesnu primjenu na kožu ruku ili stopala.
5. Lijek za uporabu prema bilo kojem od patentnih zahtjeva 1-4, naznačen time da je lijek krema, preporučeno hidrofilna krema.
6. Lijek za uporabu prema patentnim zahtjevima 1 do 5, naznačen time da sadrži od 1-10% masenog udjela alopurinola ili njegove farmaceutski prihvatljive soli, preporučeno od 1% do 8%, te još bolje od 2 do 5% masenog udjela.
7. Lijek za uporabu prema patentnom zahtjevu 1, naznačen time da sadrži 3% masenog udjela alopurinola ili njegove farmaceutski prihvatljive soli.
8. Uporaba alopurinola ili njegove farmaceutski prihvatljive soli u proizvodnji lijeka za liječenje ili prevenciju Kožne reakcije na rukama i stopalima (HFSR) izazvane terapijom multiciljnih inhibitora kinaze (MKI).
9. Alopurinol za uporabu u liječenju ili prevenciji Kožne reakcije na rukama i stopalima (HFSR) izazvane terapijom multiciljne kinaze (MKI).
10. Alopurinol za uporabu prema patentnom zahtjevu 9 u liječenju ili prevenciji Kožne reakcija na rukama i stopalima izazvane sunitinibom.
11. Alopurinol za uporabu prema patentnom zahtjevu 9 u liječenju ili prevenciji Kožne reakcija na rukama i stopalima izazvane sorafenibom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21489409P | 2009-04-29 | 2009-04-29 | |
| EP09382058A EP2246057A1 (en) | 2009-04-29 | 2009-04-29 | Use of allopurinol for the treatment of hand foot skin reaction |
| PCT/EP2010/055806 WO2010125143A1 (en) | 2009-04-29 | 2010-04-29 | Use of allopurinol for the treatment of hand foot skin reaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20131070T1 true HRP20131070T1 (hr) | 2013-12-20 |
Family
ID=40897536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20131070AT HRP20131070T1 (hr) | 2009-04-29 | 2013-11-11 | Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8623878B2 (hr) |
| EP (2) | EP2246057A1 (hr) |
| JP (1) | JP6007101B2 (hr) |
| KR (1) | KR20120049848A (hr) |
| CN (1) | CN102421436B (hr) |
| AR (1) | AR076505A1 (hr) |
| AU (2) | AU2010243594A1 (hr) |
| BR (1) | BRPI1011971A2 (hr) |
| CA (1) | CA2759085C (hr) |
| DK (1) | DK2424538T3 (hr) |
| ES (1) | ES2434366T3 (hr) |
| HK (1) | HK1168042A1 (hr) |
| HR (1) | HRP20131070T1 (hr) |
| IL (1) | IL215831A (hr) |
| ME (1) | ME01567B (hr) |
| MX (1) | MX2011011529A (hr) |
| NZ (1) | NZ595901A (hr) |
| PL (1) | PL2424538T3 (hr) |
| PT (1) | PT2424538E (hr) |
| RS (1) | RS53005B (hr) |
| RU (1) | RU2543325C2 (hr) |
| SI (1) | SI2424538T1 (hr) |
| WO (1) | WO2010125143A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013508295A (ja) | 2009-10-16 | 2013-03-07 | デューク・ユニヴァーシティ | 薬物誘発性手足症候群を治療するための組成物および方法 |
| US20140031310A1 (en) * | 2011-01-18 | 2014-01-30 | John Maki | Pharmaceutical compositions and methods for making and using them |
| JP2021506958A (ja) | 2017-12-13 | 2021-02-22 | オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． | Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法 |
| EP3782618A4 (en) * | 2018-04-16 | 2022-01-26 | OnQuality Pharmaceuticals China Ltd. | METHOD OF PREVENTING OR TREATING SIDE EFFECTS OF CANCER THERAPY |
| US20200046703A1 (en) * | 2018-08-09 | 2020-02-13 | Asymmetric Therapeutics, Llc | Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2037672T3 (es) | 1987-02-13 | 1993-07-01 | Pharm-Allergan Gmbh | Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente. |
| GB9218711D0 (en) | 1992-09-04 | 1992-10-21 | Salim Aws S M | Skin cancer treatment |
| AU4974893A (en) | 1992-09-04 | 1994-03-29 | Aws Shakir Mustafa Salim | Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol |
| JP3106817B2 (ja) | 1993-11-02 | 2000-11-06 | 富士電機株式会社 | 漏電遮断器 |
| US6284234B1 (en) | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
| US6060083A (en) | 1999-04-01 | 2000-05-09 | Topical Technologies, Inc. | Topical DMSO treatment for palmar-plantar erythrodysethesia |
| GB0013346D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| EP1343492B1 (en) | 2000-11-22 | 2006-02-01 | Rxkinetix, Inc. | Treatment of mucositis |
| US7544348B2 (en) | 2001-02-15 | 2009-06-09 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| SE0100873D0 (sv) * | 2001-03-13 | 2001-03-13 | Astrazeneca Ab | Method of treatment |
| DE60232178D1 (de) | 2001-08-29 | 2009-06-10 | Pharmakodex Ltd | Vorrichtung zur topischen verabreichung |
| US20030157191A1 (en) | 2001-11-29 | 2003-08-21 | Sound Pharmaceuticals Incorporated | Methods and compositions for ameliorating the undesirable effects of chemotherapy |
| DE10200578A1 (de) | 2002-01-09 | 2003-07-10 | Roehm Gmbh | Haft- und Bindemittel für dermale oder transdermale Therapiesysteme |
| US6979688B2 (en) | 2002-02-12 | 2005-12-27 | Ford John P | Treatment method against side-effects of chemotherapy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| CA2528378A1 (en) | 2003-06-11 | 2004-12-23 | Novacea, Inc. | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents |
| WO2004110151A1 (en) | 2003-06-11 | 2004-12-23 | Novacea, Inc. | Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments |
| US20050148910A1 (en) | 2003-12-24 | 2005-07-07 | Gregory Skover | Apparatus having a skin-contactable element containing an agent |
| JP4405326B2 (ja) | 2004-06-28 | 2010-01-27 | 株式会社東芝 | ランドリー機器 |
| PT1796660T (pt) | 2004-09-17 | 2017-02-13 | Biomas Ltd | Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta |
| MX2008015266A (es) | 2006-06-01 | 2009-02-10 | Nobera Pharma Sl | Uso del alopurinol para el tratamiento de la eritrodisestesia palmo-plantar. |
-
2009
- 2009-04-29 EP EP09382058A patent/EP2246057A1/en not_active Withdrawn
-
2010
- 2010-04-29 PL PL10719314T patent/PL2424538T3/pl unknown
- 2010-04-29 RU RU2011148355/15A patent/RU2543325C2/ru not_active IP Right Cessation
- 2010-04-29 SI SI201030402T patent/SI2424538T1/sl unknown
- 2010-04-29 CA CA2759085A patent/CA2759085C/en not_active Expired - Fee Related
- 2010-04-29 JP JP2012507765A patent/JP6007101B2/ja not_active Expired - Fee Related
- 2010-04-29 KR KR1020117028500A patent/KR20120049848A/ko active IP Right Grant
- 2010-04-29 AU AU2010243594A patent/AU2010243594A1/en not_active Abandoned
- 2010-04-29 PT PT107193146T patent/PT2424538E/pt unknown
- 2010-04-29 ME MEP-2013-127A patent/ME01567B/me unknown
- 2010-04-29 WO PCT/EP2010/055806 patent/WO2010125143A1/en active Application Filing
- 2010-04-29 DK DK10719314.6T patent/DK2424538T3/da active
- 2010-04-29 RS RS20130462A patent/RS53005B/en unknown
- 2010-04-29 BR BRPI1011971A patent/BRPI1011971A2/pt not_active IP Right Cessation
- 2010-04-29 CN CN201080019054.2A patent/CN102421436B/zh not_active Expired - Fee Related
- 2010-04-29 US US12/770,179 patent/US8623878B2/en not_active Expired - Fee Related
- 2010-04-29 NZ NZ595901A patent/NZ595901A/xx not_active IP Right Cessation
- 2010-04-29 EP EP10719314.6A patent/EP2424538B1/en active Active
- 2010-04-29 MX MX2011011529A patent/MX2011011529A/es active IP Right Grant
- 2010-04-29 ES ES10719314T patent/ES2434366T3/es active Active
- 2010-04-30 AR ARP100101462A patent/AR076505A1/es unknown
-
2011
- 2011-10-23 IL IL215831A patent/IL215831A/en not_active IP Right Cessation
-
2012
- 2012-09-07 HK HK12108803.6A patent/HK1168042A1/xx not_active IP Right Cessation
-
2013
- 2013-11-11 HR HRP20131070AT patent/HRP20131070T1/hr unknown
- 2013-11-22 US US14/087,884 patent/US20140080845A1/en not_active Abandoned
-
2016
- 2016-09-14 AU AU2016228193A patent/AU2016228193A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN102421436A (zh) | 2012-04-18 |
| IL215831A (en) | 2016-02-29 |
| EP2246057A1 (en) | 2010-11-03 |
| AU2010243594A1 (en) | 2011-11-10 |
| NZ595901A (en) | 2013-11-29 |
| RU2543325C2 (ru) | 2015-02-27 |
| AU2016228193A1 (en) | 2016-11-03 |
| AR076505A1 (es) | 2011-06-15 |
| SI2424538T1 (sl) | 2013-12-31 |
| WO2010125143A1 (en) | 2010-11-04 |
| RU2011148355A (ru) | 2013-06-10 |
| ES2434366T3 (es) | 2013-12-16 |
| US20100280051A1 (en) | 2010-11-04 |
| JP6007101B2 (ja) | 2016-10-12 |
| HK1168042A1 (en) | 2012-12-21 |
| US8623878B2 (en) | 2014-01-07 |
| JP2012525358A (ja) | 2012-10-22 |
| CA2759085C (en) | 2016-08-16 |
| CN102421436B (zh) | 2014-05-07 |
| CA2759085A1 (en) | 2010-11-04 |
| US20140080845A1 (en) | 2014-03-20 |
| MX2011011529A (es) | 2012-02-08 |
| EP2424538B1 (en) | 2013-08-14 |
| PL2424538T3 (pl) | 2014-05-30 |
| BRPI1011971A2 (pt) | 2016-04-26 |
| DK2424538T3 (da) | 2013-11-04 |
| IL215831A0 (en) | 2012-01-31 |
| ME01567B (me) | 2014-04-20 |
| PT2424538E (pt) | 2013-11-07 |
| KR20120049848A (ko) | 2012-05-17 |
| EP2424538A1 (en) | 2012-03-07 |
| RS53005B (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20131070T1 (hr) | Uporaba alopurinola za lijeäśenje kožne reakcije na rukama i stopalima | |
| RS54824B1 (sr) | Topikalna formulacija za inhibiciju jak-a | |
| PH12016501342B1 (en) | Intranasal pharmaceutical dosage forms comprising naloxone | |
| HRP20150770T1 (hr) | Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin | |
| BR112014003499A2 (pt) | compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula | |
| IL221795B (en) | Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates | |
| CL2013002210A1 (es) | Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano. | |
| IL186544A (en) | Use of Acid 3,1 - Propandysulfonic or Sodium Salt in the Preparation of Pharmaceuticals for the Treatment of aa Amyloidosis and Pharmaceuticals for the Treatment of aa Amyloidosis | |
| IL195472A0 (en) | Use of allopurinol for the treatment of palmar plantar erythrodysesthesia | |
| HRP20200424T1 (hr) | Uporaba (1r,5s)-(+)-1-(naftalen-2-il)-3-azabiciklo(3.1.0)heksana u liječenju uvjeta koji su pod utjecajem monoaminskih neurotransmitera | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| AR072951A1 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
| BR112013012100A2 (pt) | composição ou formulação farmacêutica adaptada para administração oral em forma de comprimido, comprimido revestido ou cápsula na prevenção ou tratamento de distúrbios intestinais, processo para preparar a composição ou formulação farmacêutica e uso da composição ou formulação farmacêutica | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| JP2013528627A5 (hr) | ||
| BR112015019776A2 (pt) | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos | |
| PL2640364T3 (pl) | Kompozycja farmaceutyczna zawierająca sól wodorowęglanową i jej zastosowanie jako leku w leczeniu i/lub profilaktyce kamicy moczowej i chorób pokrewnych | |
| BR112015004471A2 (pt) | formulação de tablete de composto com duas camadas constituído por atorvastatina, irbesartan e carbonato de magnésio | |
| Fernández Martínez | Prevalence, impact and treatment of primary dysmenorrhea in workers of an academic and research institute. | |
| JP2012072106A5 (hr) | ||
| BR112015017541A2 (pt) | fármaco profilático ou terapêutico para constipação | |
| WO2012108794A3 (ru) | Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии | |
| TH138893A (th) | โพรดรักของสารประกอบ nh-ที่เป็นกรด | |
| TH85141A (th) | สารสำหรับป้องกันหรือรักษาความผิดปกติของการนอน | |
| TH136339B (th) | สารรวมของเฟอร์โรควิน และ อนุพันธ์อาร์ทีมิซินิน สำหรับการรักษามาลาเรีย |